TG Therapeutics price target raised to $43 from $30 at JPMorgan

TipRanks11-26

JPMorgan raised the firm’s price target on TG Therapeutics (TGTX) to $43 from $30 and keeps an Overweight rating on the shares. The firm says that with a potential SC Briumvi formulation coming into ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2486072648?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/VaKCXGYM.Q2xBRfnsYVuuQ--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/4228d494699edc69b7f529ca87ad9ce2","is_english":true,"pubTime":"2024-11-26 19:45","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2486072648","market":"us","top_or_hot":-1,"title":"TG Therapeutics price target raised to $43 from $30 at JPMorgan","media":"TipRanks","content":"<div>\n<p>JPMorgan raised the firm’s price target on TG Therapeutics (TGTX) to $43 from $30 and keeps an Overweight rating on the shares. The firm says that with a potential SC Briumvi formulation coming into ...</p>\n\n<a href=\"https://finance.yahoo.com/news/tg-therapeutics-price-target-raised-114551747.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TG Therapeutics price target raised to $43 from $30 at JPMorgan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTG Therapeutics price target raised to $43 from $30 at JPMorgan\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-26 19:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/tg-therapeutics-price-target-raised-114551747.html><strong>TipRanks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>JPMorgan raised the firm’s price target on TG Therapeutics (TGTX) to $43 from $30 and keeps an Overweight rating on the shares. The firm says that with a potential SC Briumvi formulation coming into ...</p>\n\n<a href=\"https://finance.yahoo.com/news/tg-therapeutics-price-target-raised-114551747.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TG","symbol_name":"特里迪加","start_time":0,"source_url":"https://finance.yahoo.com/news/tg-therapeutics-price-target-raised-114551747.html","article_id":"2486072648","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/VaKCXGYM.Q2xBRfnsYVuuQ--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/4228d494699edc69b7f529ca87ad9ce2"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/tg-therapeutics-price-target-raised-114551747.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2486072648","pubTimestamp":1732621551,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"JPMorgan raised the firm’s price target on TG Therapeutics  to $43 from $30 and keeps an Overweight rating on the shares. The firm says that with a potential SC Briumvi formulation coming into view beginning in the first half of 2025, it updated TG’s model to reflect risk adjusted Briumvi forecasts within the at-home/self-administered anti-CD20 segment of relapsing multiple sclerosis. At $3.5B, the analyst’s peak Briumvi SC forecast assumes market entry beginning in 2028 and ultimately garnering 35% share of the self-administered CD20 segment. JPMorgan sees an increasingly attractive setup to TG shares in the mid-term.Unlock your investing potential with TipRanks Premium - Now At 40% OFF!Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter. Unusually active option classes on open November 14th. Reporters tweets about ‘vague whispers’ of bid interest in TG Therapeutics. TG Therapeutics call volume above normal and directionally bullish","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"TG":"特里迪加","TGTX":"TG Therapeutics Inc."},"translate_title":"摩根大通将TG Therapeutics目标价从30美元上调至43美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TG":1,"TGTX":1},"content_text":"JPMorgan raised the firm’s price target on TG Therapeutics (TGTX) to $43 from $30 and keeps an Overweight rating on the shares. The firm says that with a potential SC Briumvi formulation coming into view beginning in the first half of 2025, it updated TG’s model to reflect risk adjusted Briumvi forecasts within the at-home/self-administered anti-CD20 segment of relapsing multiple sclerosis. At $3.5B, the analyst’s peak Briumvi SC forecast assumes market entry beginning in 2028 and ultimately garnering 35% share of the self-administered CD20 segment. JPMorgan sees an increasingly attractive setup to TG shares in the mid-term.\n\nDon't Miss our Black Friday Offers:\n\nUnlock your investing potential with TipRanks Premium - Now At 40% OFF!\nMake smarter investments with weekly expert stock picks from the Smart Investor Newsletter\n\n\n\nPublished first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>\n\n\nSee today’s best-performing stocks on TipRanks >>\n\n\nRead More on TGTX:\n\nUnusually active option classes on open November 14th\nReporters tweets about ‘vague whispers’ of bid interest in TG Therapeutics\nTG Therapeutics call volume above normal and directionally bullish\nTG Therapeutics price target raised to $45 from $43 at Ladenburg\nTG Therapeutics Boosts Revenue Outlook Amidst Growth","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2486072648"}